AURA AU-011: $725M Choroidal Melanoma Phase 3 Primer

Aura Biosciences trades at $7.01 with a market cap of $725 million. The company has one asset, bel-sarotmecan (AU-011), and one trial that matters: the Phase 3 CoMpass study in early choroidal melanoma. That trial completed enrollment in June 2026, and topline data for the 15-month primary endpoint is expected in the second half of 2027. This is a binary biotech bet in its purest form. If CoMpass succeeds, AU-011 becomes the first FDA-approved therapy for early choroidal melanoma, a rare eye cancer with no approved drugs. If it fails, AURA is a $725 million company with a depleted pipeline and a cash runway that runs out in 2028.

The question is whether $725 million prices in the right probability of success. It underprices it, modestly.

The Disease: Early Choroidal Melanoma Has Zero Approved Drugs

Choroidal melanoma is the most common form of uveal melanoma, accounting for roughly 90% of cases. The choroid is the vascular layer between the sclera and the retina. Incidence runs 5 to 7.5 cases per million annually in populations of European descent, translating to approximately 11,000 new patients per year across the US and Europe. About 80% are diagnosed at an early stage.

The brutal part: there are no FDA-approved drugs for early-stage disease. The standard of care is local treatment, either plaque brachytherapy (iodine-125 or ruthenium-106 radioactive plaques sutured to the eye wall), proton beam radiation, or enucleation (surgical removal of the eye). Plaque brachytherapy and proton beam both carry risks of vision loss, radiation retinopathy, and optic neuropathy. Enucleation removes the eye entirely. Patients choose between losing vision and losing the eye.

Approximately 50% of choroidal melanoma patients eventually develop metastatic disease, which spreads hematogenously to the liver and carries a devastating prognosis. The only approved drug for uveal melanoma at any stage is KIMMTRAK (tebentafusp), approved in January 2022 for HLA-A*02:01-positive patients with unresectable or metastatic uveal melanoma. KIMMTRAK does not address early-stage disease. It is a T-cell redirector for patients whose cancer has already spread.

This is the market AU-011 targets: early-stage patients who today face radiation or surgery, with no pharmacologic option.

The Mechanism: A Virus-Like Drug Conjugate Activated by Light

AU-011 is a virus-like drug conjugate (VDC). The construct uses a human papillomavirus L1 protein virus-like particle decorated with approximately 270 copies of a phthalocyanine photosensitizer dye. The VLP targets cell surface heparan sulfate proteoglycans, overexpressed on melanoma cells. Once the conjugate binds, activation requires 690nm red light delivered via a medical laser through a fiber optic probe placed suprachoroidally or transpupillary.

Upon light activation, the phthalocyanine dye generates reactive oxygen species that destroy tumor cells through two mechanisms: direct necrosis of cells that have taken up the conjugate, and immunogenic cell death that triggers a host antitumor immune response. The dual mechanism matters because it means AU-011 is not just a local ablative therapy. It also generates systemic immunity that could address micrometastatic disease, the silent killer that drives the 50% metastasis rate.

The treatment is administered in an ophthalmology procedure setting, not an operating room. Two light activations per session, with the option for retreatment. This is fundamentally different from radiation, which is a one-time event with cumulative tissue damage.

The Phase 3 CoMpass Trial: What the Data Needs to Show

The CoMpass trial (NCT06007690) is a global, randomized, masked, sham-controlled Phase 3 study in first-line early choroidal melanoma. The trial enrolled 108 patients randomized 2:1:2 to receive either the 80 microgram high-dose regimen (n=40), the 40 microgram low-dose regimen (n=20), or sham control (n=40). The trial operates under a Special Protocol Assessment agreement with the FDA, meaning the agency has agreed the design and analysis would support a marketing application if the endpoint is met.

The primary endpoint is time to tumor progression, assessed when the last patient completes 15 months of follow-up. The first key secondary endpoint is a composite time-to-event analysis comparing tumor control and visual acuity of the high-dose regimen to sham.

The trial is powered at greater than 90%. That is an aggressive power calculation for a rare disease trial with 108 patients. It signals confidence from Aura’s biostatistics team that the effect size from Phase 2 will hold in the larger cohort.

The Phase 2 data showed an 80% tumor control rate (8 of 10 Phase 3-eligible patients who received the active regimen). Tumor control means the tumor did not progress, did not require salvage radiation or enucleation, and the patient retained their eye. The sham control provides the counterfactual: without treatment, what fraction of patients progress within 15 months?

What the data needs to show to re-rate the stock: a statistically significant separation in time to progression between the high-dose arm and sham control. If the high-dose arm shows a hazard ratio below 0.5 against sham with a p-value under 0.05, the stock re-rates substantially. If the hazard ratio is between 0.5 and 0.7, the drug likely gets approved but the effect size will limit the commercial story. If the hazard ratio exceeds 0.7 or misses significance, the trial fails and the stock loses 50 to 70%.

The Valuation: $725M Against a $340M Market

AURA’s $725 million market cap looks modest until you size the market. Industry analysts estimate the total uveal melanoma market at approximately $340 million across the US and seven major markets as of 2023, projected to grow through 2034. That figure is dominated by KIMMTRAK in the metastatic setting.

Early choroidal melanoma is a different market. If AU-011 is approved as the first drug for early-stage disease, it would capture patients who today go straight to radiation or surgery. At a hypothetical price of $50,000 per treatment course (consistent with orphan drug pricing for rare oncology therapies), and 3,000 treated patients per year across the US and Europe (a fraction of the 11,000 annual incidence), peak sales could reach $150 million. Apply a 4x peak sales multiple for a pre-approval oncology asset with orphan exclusivity, and the NPV is $600 million. That roughly equals the current market cap.

The market is pricing AU-011 at a probability-adjusted NPV that assumes roughly 50% odds of approval and successful commercialization. The probability of Phase 3 success is higher than 50% given the SPA agreement, the 90% power calculation, and the Phase 2 tumor control signal. But the market is also small, and even with approval, the revenue ceiling is limited by incidence. This is a $1 to $1.5 billion market cap story on success, not a $5 billion story.

For comp context, biotech valuation methods apply a 3-8x peak sales multiple to pre-approval assets; AURA has no revenue and one Phase 3 asset. The $725 million market cap is a pure probability bet on a single trial.

The Competitive Picture: No Direct Competitor in Early-Stage Disease

No company is developing a pharmacologic therapy for early choroidal melanoma. The competitive picture for AU-011 is not other drugs. It is radiation and surgery.

Plaque brachytherapy (iodine-125) is the standard for medium-sized tumors. The COMS medium tumor trial established equivalent survival to enucleation, but plaque therapy requires two surgeries (suture the plaque, then remove it), a hospital stay, and carries long-term risks of radiation retinopathy and optic neuropathy. Proton beam radiation offers precise delivery but requires specialized facilities and causes similar vision toxicity.

AU-011’s differentiation is that it is a non-surgical, non-radioactive, repeatable local therapy that preserves the eye and also generates systemic antitumor immunity. If it works, it shifts the treatment approach from radiation to pharmacologic intervention. But it needs to prove noninferiority to the COMS plaque brachytherapy standard in terms of tumor control, and it needs to demonstrate a vision preservation advantage. The CoMpass trial’s secondary endpoint on visual acuity is where that case gets made.

The broader oncology biotech 2026 catalysts picture is dominated by larger companies. AURA is a micro-cap outlier with a cleaner binary setup: one trial, one endpoint, one answer.

Risks: Cash, Timeline, and Historical Control Design

Three risks matter.

First, the timeline shifted. The brief that prompted this analysis stated a H2 2026 readout. Aura’s March 30, 2026 press release confirmed the 15-month primary endpoint topline data is expected in the second half of 2027, not 2026. Enrollment completed in June 2026, and the last patient’s 15-month follow-up runs through late 2027. This means AURA trades on trial enrollment completion and Phase 2 data updates for another 12 to 15 months before the binary event. The stock could drift lower on absence of catalysts.

Second, cash. As of December 31, 2025, Aura had $144.2 million in cash and marketable securities. In May 2026, the company raised $299 million in an oversubscribed equity offering at $6.00 per share, diluting existing shareholders by roughly 40%. The post-financing cash position is expected to fund operations into the second half of 2028, past the CoMpass readout. But the dilution is real: the share count has grown 29.8% in one year per SEC filings, from approximately 85 million to 110.3 million shares. Investors who held before the offering absorbed significant dilution to fund the trial through to readout.

Third, the sham-controlled design is a strength, but the trial does not compare AU-011 directly to plaque brachytherapy. The FDA accepted the sham control under the SPA, but the clinical community may question whether a drug that has not been compared to the standard of care can displace radiation in practice. The clinical trial endpoints that matter here are tumor progression and vision preservation, and both must be met to change practice. Meeting the primary endpoint without a vision advantage would give AURA an approved drug that physicians are reluctant to use.

Verdict: A High-Conviction Binary Bet at Fair Price

AURA at $725 million is pricing AU-011 at roughly a coin flip. The SPA agreement, the 90% power calculation, the 80% Phase 2 tumor control rate, and the complete absence of any approved drug in the indication all argue the probability of success is higher than 50%. The estimate is 60 to 65% probability that CoMpass hits its primary endpoint.

At 65% probability and a $1.2 billion success case (4x peak sales of $150M plus platform optionality in NMIBC), the expected value is approximately $780 million, modestly above the current $725 million market cap. The stock is fairly valued with slight upside to the probability estimate.

Position sizing matters here. This is a single-asset, single-trial biotech with no revenue and a 12 to 15 month wait for the binary event. The phase 3 readouts framework is relevant: do not size a pre-readout position larger than 1 to 2% of a biotech portfolio. The downside on a miss is 50 to 70%, and the cash runway ends in 2028, meaning a failed trial leaves limited room to pivot.

The contrarian case: the market ignores the NMIBC program. AU-011 is also in a Phase 1/2 trial in non-muscle invasive bladder cancer (NCT05483868), where early data showed multiple clinical complete responses. The bladder program is years behind, but it represents optionality the $725 million market cap does not credit. If CoMpass succeeds, the platform value across both indications supports a re-rating beyond the choroidal melanoma NPV.

Hold a small position (1 to 2% of a biotech portfolio) ahead of the H2 2027 readout. The risk-reward is asymmetric but not extreme. The stock is fairly priced for the probability, and the timeline means capital is tied up for over a year with no intermediate catalyst. Wait for pullbacks below $6.00 to add. Do not chase above $8.00.

Correction note: the brief that prompted this analysis described AU-011’s Phase 3 as a bladder cancer (NMIBC) trial. That is incorrect. The Phase 3 CoMpass trial is in early choroidal melanoma. AU-011 has a separate Phase 1/2 program in NMIBC that is not in registration-enabling trials. The brief also stated a H2 2026 readout; the confirmed timeline is H2 2027 per Aura’s March 30, 2026 press release.